

What Can We Expect More from CDK4/6i in Treating HR+HER2- mBC Patient?

Dwan-Ying Chang, MD

Randomized phase III clinical trials had demonstrated consistent benefits of adding ribociclib to endocrine therapies; regardless of menopausal status, the combination improved not only progression free survival but also overall survival in advanced HR+/HER2- breast cancer patients without hampering quality of life. Moreover, in a typical challenging population: young patients with either substantial visceral burden or rapidly progressed disease for whom combination chemotherapy deemed necessary; ribociclib plus ovarian function suppression and endocrine therapy showed comparable objective response rate and superior progression free survival to combination chemotherapies in RightChoice study. The positive finding shed some light in further paradigm shift and let's explore how much can CDK4/6 inhibitors changed patient's life.